This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
It’s been hard to be a shareholder in copper and gold stock Freeport-McMoRan (NYSE:FCX) over the last few years. First, there was the collapsing copper and gold prices due to the recession. Then, it was there was the company’s poorly timed forays into the oil and gas sectors.
RIO BLT BHP NEM BHPBF BBL FCX BHP BHPLF
U.S. equities continue to trade nervously at the start of U.S. trade tariffs on $34 billion of Chinese imports — an act that will then be met with countervailing tariffs on U.S. imports by the Chinese. While far more in potential tariffs have been announced by both sides as threats, neither side is showing any evidence of being interested in backing down from what looks like a worsening cycle of escalation.
MS.PRI TLT NEM MS.PRK PAAS MS.PRE MS.PRF MS.PRG MS MS.PRA
We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.
WPM NGD GFI.WI ABX NEM NGDAF K GDX NGD SLW SLW ELD KGC GFI GFIOF EGO ABX
Newmont Mining Corporation (NEM - Free Report) said that its Twin Creeks Underground expansion project has achieved commercial production and the project was completed on schedule for $42 million (below initial guidance of $45-$55 million). The project enables the company to add higher-grade, lower-cost gold production at its Twin Creeks operation in Nevada. The mine will add 30,000-40,000 ounces of gold per annum at all-in sustaining costs of $650-$750 per ounce for the initial five years of production.
ABX WLK NEM CC ABX
In the middle of remote Central Australia, work has quietly begun on a 450-kilometre natural gas pipeline owned in part by the Chinese company that launched a $13 billion takeover of Australia's largest gas network operator earlier this month.
NEM HGKGF HGKGY
WINNEMUCCA, Nev., June 26, 2018 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American:PZG) ("Paramount”) announced today that John W. Seaberg has joined its board of directors as Executive Chairman. As a member of Paramount’s executive leadership team Mr. Seaberg will be responsible for Capital Markets.
SA NEM KDX SEA HL KLDX HL.PRB PZG
The past few weeks have been surprisingly painful for fans and followers of gold stocks. The SPDR Gold Shares Fund (NYSEARCA:GLD), an ETF that serves as a broad proxy for the overall gold market, has lost more than 6% of its value since peaking in March. Meanwhile, gold prices themselves have fallen nearly 8% for the same timeframe.
MS.PRI NEM MS.PRK MS.PRE MS.PRF GDX MS.PRG MS MS.PRA IAG GG GDXJ
TOKYO, June 21 (Reuters) - Japanese trading house Sumitomo Corp on Thursday said it had agreed to buy a 5-percent stake in the Yanacocha gold mine in Peru for $48 million, as it looks to boost its assets in the metals sector.
NEM AAUKF SSUMF AAL NGLOY
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to NEM / Newmont Mining Corp. on message board site Silicon Investor.
as of ET